Evidence map›Paper›PMID 26843289›Full record

ReviewNature reviews. Cardiology2016

Ischaemic conditioning and reperfusion injury.

Derek J Hausenloy, Derek M Yellon

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04284592 (Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery), which is not on this map. Cited by 332 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
332citing papers in PubMed, 10 pooled it
48.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04284592 nacompletednot on this map

Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery: a Randomised Controlled Study

TypeinterventionalSponsorJosé García de la AsunciónRan2012 to 2017Enrolled70ConditionsIschemia-reperfusion InjuryArmsRemote ischemic post-conditioning (RIP)
3 · Its place in the literature

Who cites it

332 citing papers in PubMed, 10 syntheses or guidelines pooled it, 559 citations in OpenAlex.

  1. Pooled it
  2. Remote ischaemic conditioning for preventing and treating ischaemic stroke.The Cochrane database of systematic reviews · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

272 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Derek J HausenloyCardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore 169857, Singapore.
Derek M YellonThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK.
University College London · GB

Funding

British Heart Foundation FS/10/039/28270British Heart Foundation PG/09/106/28142British Heart Foundation RG/08/015/26411Medical Research Council MR/K002066/1
6 · The paper itself

Abstract

The 30-year anniversary of the discovery of 'ischaemic preconditioning' is in 2016. This endogenous phenomenon can paradoxically protect the heart from acute myocardial infarction by subjecting it to one or more brief cycles of ischaemia and reperfusion. Apart from complete reperfusion, this method is the most powerful intervention known for reducing infarct size. The concept of ischaemic preconditioning has evolved into 'ischaemic conditioning', a term that encompasses a number of related endogenous cardioprotective strategies, applied either directly to the heart (ischaemic preconditioning or postconditioning) or from afar, for example a limb (remote ischaemic preconditioning, perconditioning, or postconditioning). Investigations of signalling pathways underlying ischaemic conditioning have identified a number of therapeutic targets for pharmacological manipulation. Over the past 3 decades, a number of ischaemic and pharmacological cardioprotection strategies, discovered in experimental studies, have been examined in the clinical setting of acute myocardial infarction and CABG surgery. The results from many of the studies have been disappointing, and no effective cardioprotective therapy is currently used in clinical practice. Several large, multicentre, randomized, controlled clinical trials on cardioprotection have highlighted the challenges of translating ischaemic conditioning and pharmacological cardioprotection strategies into patient benefit. However, a number of cardioprotective therapies have shown promising results in reducing infarct size and improving clinical outcomes in patients with ischaemic heart disease.

Indexed as

AnimalsCardiovascular AgentsHumansIschemic PostconditioningIschemic PreconditioningIschemic Preconditioning, MyocardialMyocardial InfarctionMyocardial Reperfusion InjuryTreatment OutcomeCardiovascular Agents

Identifiers

PMID26843289
OpenAlexW2281735941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.